|
摘要：
|
|
摘要：目的 运用Meta分析系统性评价异甘草酸镁治疗失代偿期肝硬化患者的有效性及
安全性。方法 计算机检索万方数据库、中国生物医学文献数据库、中国知网、维普数
据库，PubMed、the Cochrane Library及EMBase数据库，检索时间为建库至2023年5月
15日。纳入的研究类型为随机对照试验（randomized controlled trial，RCT），研究对
象为失代偿期肝硬化患者，试验组采用异甘草酸镁治疗，对照组不采用异甘草酸镁治
疗。由2名研究者独立筛选文献并提取数据进行系统性评价。结果 纳入16篇文献，共计
1525例患者，其中试验组764例，对照组761例。试验组患者临床有效率显著优于对照
组（OR = 4.07，95% CI：2.80～5.90，P ＜ 0.001），且无不良事件增加（OR = 0.66，
95% CI：0.35～1.26，P = 0.210）。试验组患者丙氨酸氨基转移酶（SMD =－1.63，
95% CI：－2.10～－1.16，P ＜ 0.001）、天冬氨酸氨基转移酶（SMD = －1.95，95% CI：
－2.64～－1.27，P ＜ 0.001）和总胆红素（SMD = －1.49，95% CI：－2.15～－0.82，
P ＜ 0.001）水平显著低于对照组，差异均具有统计学意义。结论 异甘草酸镁治疗失代
偿期肝硬化患者的效果显著，可提高临床有效率及改善肝功能，安全性良好。
|
|
Abstract: Objective To systematically evaluate the efficacy and safety of magnesium
isoglycyrrhizinate in the treatment of patients with decompensated liver cirrhosis by Meta-analysis.
Methods Wanfang Data, Chinese Biomedical Literature Database, China National Knowledge
Infrastructure, VIP Database, PubMed, the Cochrane Library and EMBASE were searched for
references from database establishment to May 15th, 2023. Randomized controlled trial (RCT)
studies were included, and the research subjects were patients with decompensated liver cirrhosis.
Patients in experimental group were treated with magnesium glycyrrhizinate, while patients in
control group were not treated with magnesium glycyrrhizinate. Two researchers screened the literature
and extracted data for systematic evaluation independently. Results A total of 1525 patients were
included in 16 studies, including 764 cases in experimental group and 761 cases in control group.
The clinical efficacy of patients in experimental group was significantly higher than those in control
group (OR = 4.07, 95% CI: 2.80～5.90, P ＜ 0.001) and there was no increase in adverse events
(OR = 0.66, 95% CI: 0.35～1.26, P = 0.210). Alanine aminotransferase (SMD =－1.63, 95% CI:
－2.10～－1.16, P ＜ 0.001), aspartate aminotransferase (SMD = －1.95, 95% CI: －2.64～－1.27,
P ＜ 0.001) and total bilirubin (SMD = －1.49, 95% CI: －2.15～－0.82, P ＜ 0.001) levels of
patients in experimental group were significantly lower than those in control group, the differences
were statistically significant. Conclusions Magnesium glycyrrhizinate has a significant therapeutic
effect on patients with decompensated liver cirrhosis, which can improve clinical efficacy and liver
function, with good safety.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|